Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies

NCT01117623 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01117623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01117623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2007
Completion date
November 30, 2013
Enrollment
86 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm